<DOC>
	<DOCNO>NCT01948843</DOCNO>
	<brief_summary>Certain cancer require amino acid arginine . Arginine deiminase ( ADI ) enzyme microbe degrade arginine . ADI formulate polyethylene glycol , use treat patient cancer require arginine . In study , ADI combine well know chemotherapy Doxorubicin safety potential efficacy combination explore patient HER2 Negative Metastatic Breast Cancer .</brief_summary>
	<brief_title>Ph 1 ADI-PEG 20 Plus Doxorubicin ; Patients With HER2 Negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Biopsy proven HER2 negative metastatic breast cancer ( dose escalation portion MTD expansion portion ) advance solid tumor ( dose escalation portion ) . 2 . ASS deficiency ( define &lt; 50 % ASS expression ) demonstrate tissue specimen Immunohistochemistry ( IHC ) . Cytology fine need aspirate specimen acceptable ASS testing . 3 . Unresectable disease subject refuse surgery . 4 . Measurable disease assess RECIST 1.1 criterion ( Appendix A ) . 5 . Failed available therapy know confer clinical benefit 4 prior line chemotherapy metastatic disease . 6 . Time treatment failure doxorubicin contain regimen ≥ 12 month previously treat doxorubicin . 7 . Age ≥ 18 year . 8 . ECOG performance status 0 2 . 1 . Serious infection require treatment systemically administer antibiotic time study entrance , infection require systemic antibiotic therapy within 7 day prior first dose study treatment . 2 . Prior epirubicin exposure &gt; 600 mg/m2 . 3 . Pregnancy lactation . 4 . Expected noncompliance . 5 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( New York Heart Association Class III IV ) , cardiac arrhythmia , psychiatric illness , social situation would limit compliance study requirement . 6 . Subjects anticancer treatment prior enter study recover baseline ( except alopecia ) ≤ Grade 1 AEs , deem irreversible effect prior cancer therapy . AEs &gt; Grade 1 consider safety risk Sponsor Investigator may allow upon agreement . 7 . Subjects history another primary cancer , include coexistent second malignancy , exception : ) curatively resect nonmelanoma skin cancer ; b ) curatively treated cervical carcinoma situ ; c ) primary solid tumor know active disease present opinion Investigator affect subject outcome set breast cancer diagnosis . 8 . Subjects treat ADIPEG 20 previously .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HER2 Negative Metastatic Breast Cancer</keyword>
</DOC>